Cliantha Research

Phase 2

Ahmedabad, United StatesFounded 2003cliantha.com

Cliantha Research is a leading Indian CRO with a 21-year history of excellence, operating under the motto 'Science with Integrity.' The company offers end-to-end clinical trial services, including early and late-phase studies, biometrics, and specialized research in areas like respiratory and dermatology. It maintains a strong regulatory compliance record with agencies like the USFDA, WHO, MHRA, and Health Canada, and has expanded its capabilities with advanced infrastructure like environmental exposure chambers and LCMS/MS systems.

Founded

2003

AI Company Overview

Technology Platform

Integrated CRO service platform featuring specialized clinical research infrastructure, including Environmental Exposure Chambers for respiratory trials, Occlusive Dermal Delivery (Hill Top) Chambers for dermatology, and advanced bioanalytical labs with LC-MS/MS systems.

Funding History

Total raised: $20M

Series A$15MUndisclosedAug 15, 2021

Seed$5MUndisclosedJun 15, 2019

Opportunities

Growth opportunities include expanding its large molecule and biologic trial services, leveraging its unique environmental exposure and dermatology chambers to secure niche studies, and capitalizing on the increasing outsourcing of clinical trials to cost-effective, high-quality regions like India.

Strategic partnerships with virtual or small biotech companies represent another avenue for growth.

Risk Factors

Key risks include intense competition from global and local CROs, regulatory compliance failures that could damage its reputation, dependence on a limited client base, and operational risks associated with the complex execution of clinical trials.

Talent acquisition and retention in a competitive market also pose a challenge.

Competitive Landscape

Cliantha competes with large multinational CROs (e.g., IQVIA, ICON) and other Indian CROs (e.g., Syngene, Lambda). Its differentiation is built on a strong 15+ year regulatory track record with major health authorities, ownership of specialized research infrastructure (exposure/chambers), and its position as a full-service, integrated CRO based in the cost-advantaged Indian market.